company insight

First of all, could you explain the activity of Biocorp to our readers?

BIOCORP is a drug delivery device company established 20 years ago with extensive experience in providing services to Pharmaceutical companies. We first started our work by providing reconstitution solution. From there, we developed a portfolio of safety system products in prefilled syringes and, four years ago, we entered a new area by developing smart devices in the drug delivery segments with the ambition to become one of the worldwide leaders. 

01 / According to you, what are the current issues about Drug delivery?

Some current issues would be related to regulatory constraints: regulation first came in the United States and now Europe, leading to provide needlestick protection to prefilled syringes range.

With regard to patients, we have observed over the past two years that addressing the problem of adherence may be a determining factor: what about the overall relevance of a drug when it is not correctly taken by a patient? It also has a social impact as well with the product being covered by insurance companies, whether they are public or private. You must have a clear idea of what the patient is doing correctly or not. This is where providing tools to connect devices does really make sense. That’s why Biocorp has spent a lot of time and money over the past two years developing platforms to tackle this issue.

02 / How is Biocorp part of drug delivery advances?

We aim to develop a solution that meets the needs of patients or pharmaceutical companies, or both! It is about providing the simplest and best solution, that is to say a simple solution to qualify from a regulatory point of view profitable enough to be widely accepted and promoted to the patient. We have tried to move forward with this solution and advance in this segment with a solution as simple as possible and very easy to use as we think it is a very important asset for these devices to be used in the long term, it’s our goal.

03 / How important is connectivity in this area? How does it improve patients’ life?

It's not about connectivity by itself, which means it's not just adding a connectivity feature without thinking. A more global consideration is necessary: why is connectivity important for the patient? How would the device interface with other data that the patient already has? The case of diabetes is a very good example where you can have different types of data. That’s why we want to make sure that the data you get from our devices is easy to collect and easy to use without adding complexity! Life is complicated enough for patients without adding complexity! That's why connectivity is useful when providing an extra service.

04 /  Don’t you think that collecting and storing data might frighten patients?

I think the mindset of patients has changed by seeing the benefits of connectivity versus some risks. However, there is always a balance between advantages and disadvantages. We have the European market and the US market: both markets venture to accept smarter surveillance devices. The United States and Europe have guidelines and regulations that we follow closely. Biocorp has a team dedicated to cybersecurity that ensures the data; we respect the rules and we follow the guidelines.

It is important to say that the data must be secured, but it must also be available when necessary. At the same time, giving data to other providers will offer additional services to patients.

05 /  What do you see as the next big challenges in drug delivery? Which are next milestones for Biocorp?

To me, there is a global tendency of launching new devices on the market with “intelligent” features and it is beneficial for BIOCORP not being alone in that game. However, we want to be the most important player in that field and define new standards of care. We are planning a commercial launch next year, which is obviously an important step. We will provide a drug delivery device on the market and will obtain real-time data from patients, as well as acceptance and rate of use of the program.

Share this article